CaaMTech, in collaboration with the Manke Lab at UMass Dartmouth, has has announced the syntheses and solid-state characterization of two novel monoalkyltryptamines: N-ethyl-4-hydroxytryptamine (4-HO-NET) and 4-hydroxy-N-propyltryptamine (4-HO-NPT). The peer-reviewed study, titled “Syntheses and structures of two norpsilocin derivatives: N-ethyl-4-hydroxytryptamine (4-HO-NET) and 4-hydroxy-N-propyltryptamine (4-HO-NPT),” was published in the journal Acta Crystallographica Section E. The research was co-authored by Marilyn Naeem, Ph.D., Andrew R. Chadeayne, Ph.D., James A. Golen, Ph.D., and Professor David R. Manke, representing a continuation of their productive, longstanding collaboration in mapping structural and chemical properties of psychedelic-inspired tryptamines.
While the vast majority of academic, clinical, and commercial interest in psychedelic drug development has historically focused on dialkyltryptamines, such as DMT, 5-MeO-DMT, psilocin, and psilocybin, closely related monoalkyltryptamines remain far less explored. CaaMTech’s pioneering research in this field began with exploring naturally occurring “minor” tryptamines in magic mushrooms, such as baeocystin and norpsilocin, and has since expanded into systematic studies mapping the structure-activity relationships of synthetic monoalkyltryptamine analogues.
Monoalkyltryptamines represent a distinct class of serotonergic chemicals that could present pharmacology not accessible through traditional dialkyltryptamines. Minimal structural modifications can profoundly alter a drug’s effects. The removal of a single alkyl group, such as a methyl group, from the traditional dimethyltryptamine backbone can significantly alter lipophilicity, central nervous system exposure, metabolism, receptor activity, and transporter pharmacology, creating new opportunities for engineering optimized psychiatric therapeutics. For instance, norpsilocin (4-HO-NMT) and the newly synthesized N-ethyl-4-hydroxytryptamine (4-HO-NET) differ by only a single carbon atom in their N-substituent. Yet, recent studies show important differences in their ability to cross the blood-brain barrier, attain central nervous system exposure, and produce 5-HT2A-mediated behavioral effects in preclinical models.
Fundamental chemical research lays a stable foundation for downstream pharmacological research and development of molecules like monoalkyltryptmamines into pharmaceutical therapies. The paper’s authors point out that monoalkyltryptamines are exceptionally rare in the Cambridge Structural Database (CSD): out of the hundreds of thousands of organic crystal structures documented, only ten monoalkyltryptamines had ever been reported prior to this publication, nearly all of which were synthesized and solved by CaaMTech and UMass Dartmouth in just the last few years. Adding these two structures significantly expands the structural reference library for this historically neglected class of compounds.
“I am eager to see where this work takes us,” said CaaMTech CEO, Dr. Andrew Chadeayne. “Monoalkyltryptamines have been ignored relative to dialkyltryptamines, yet could prove equally promising as next-generation serotonergic drugs.”